La Jolla Pharmaceutical Top Management

LJPCDelisted Stock  USD 6.22  0.00  0.00%   
La Jolla employs about 61 people. The company is managed by 11 executives with a total tenure of roughly 102 years, averaging almost 9.0 years of service per executive, having 5.55 employees per reported executive. Evaluation of La Jolla's management performance can provide insight into the firm performance.
George Tidmarsh  CEO
President CEO, Secretary, Director
Saiid Zarrabian  Chairman
Independent Chairman of the Board
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

La Jolla Management Team Effectiveness

The company has return on total asset (ROA) of 1.64 % which means that it generated a profit of $1.64 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0544 %, meaning that it created $0.0544 on every $100 dollars invested by stockholders. La Jolla's management efficiency ratios could be used to measure how well La Jolla manages its routine affairs as well as how well it operates its assets and liabilities.

La Jolla Workforce Comparison

La Jolla Pharmaceutical is currently regarded as number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 169,127. La Jolla adds roughly 61.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 10.08 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 4.68 %, which suggests for every 100 dollars of sales, it generated a net operating income of $4.68.

La Jolla Notable Stakeholders

A La Jolla stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as La Jolla often face trade-offs trying to please all of them. La Jolla's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting La Jolla's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
George TidmarshPresident CEO, Secretary, DirectorProfile
Saiid ZarrabianIndependent Chairman of the BoardProfile
Jennifer CarverSenior Vice President OperationsProfile
Dennis MulroyCFOProfile
Chester ZygmontDirector of FinanceProfile
Craig JohnsonIndependent DirectorProfile
Robert RosenDirectorProfile
Laura DouglassIndependent DirectorProfile
James RolkeVP of RandDProfile
Lakhmir ChawlaChief Medical OfficerProfile
Darryl WellinghoffChief Commercial OfficerProfile

About La Jolla Management Performance

The success or failure of an entity such as La Jolla Pharmaceutical often depends on how effective the management is. La Jolla management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of LJPC management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the LJPC management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. La Jolla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 61 people.
The data published in La Jolla's official financial statements usually reflect La Jolla's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of La Jolla Pharmaceutical. For example, before you start analyzing numbers published by LJPC accountants, it's critical to develop an understanding of what La Jolla's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of La Jolla's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, La Jolla's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in La Jolla's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of La Jolla Pharmaceutical. Please utilize our Beneish M Score to check the likelihood of La Jolla's management manipulating its earnings.

La Jolla Workforce Analysis

Traditionally, organizations such as La Jolla use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare La Jolla within its industry.

La Jolla Manpower Efficiency

Return on La Jolla Manpower

Revenue Per Employee852.6K
Revenue Per Executive4.7M
Net Income Per Employee85.9K
Net Income Per Executive476.4K
Working Capital Per Employee1.3M
Working Capital Per Executive7.2M
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Consideration for investing in LJPC Stock

If you are still planning to invest in La Jolla Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the La Jolla's history and understand the potential risks before investing.
Stocks Directory
Find actively traded stocks across global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories